7 Subcutaneous semaglutide was approved in 2021 and 2022 as Wegovy for weight loss in patients 12 and older after the STEP1 trial showed patients who took subcutaneous semaglutide had a -14.9% body weight reduction (-15.3kg) compared to -2.4% (-2.6kg) with placebo after 68 weeks
Kuhse, J
Diabetes Res Clin Pract 138:271281 Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF et al (2013) Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Doctors treat insomnia according to the cause and may recommend a combination of lifestyle and sleep habit changes, CBT, and medication
doi: 10.21053/ceo.2016.9.1.80 29 FellerLChandranRKramerBKhammissaRAAltiniMLemmerJ
Are bowel purgatives and prokinetics useful for small-bowel capsule endoscopy